Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO) in renal cell carcinoma patients with bone metastases

Next Previous
X
Search
Trial Profile

Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO) in renal cell carcinoma patients with bone metastases

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases
  • Focus Adverse reactions
  • Acronyms EIFFEL

    • Most Recent Events

    • 07 Nov 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Oct 2020.
    • 07 Nov 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 08 Jul 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top